Evidence map›Paper›PMID 27902773›Full record

ArticlePloS one2016

Genomic Landscape of Experimental Bladder Cancer in Rodents and Its Application to Human Bladder Cancer: Gene Amplification and Potential Overexpression of Cyp2a5/CYP2A6 Are Associated with the Invasive Phenotype.

Kazuhiro Kanemoto, Katsuhiro Fukuta, Noriyasu Kawai, Keiichi Tozawa, Masako Ochiai, Koji Okamoto, Sumiko Ohnami, Hiromi Sakamoto, Teruhiko Yoshida, Yae Kanai and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Kazuhiro KanemotoDivision of Cancer Development System, National Cancer Center Research Institute, Tokyo, Japan.
Katsuhiro FukutaDepartment of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Noriyasu KawaiDepartment of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Keiichi TozawaDepartment of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Masako OchiaiDivision of Cancer Development System, National Cancer Center Research Institute, Tokyo, Japan.
Koji OkamotoDivision of Cancer Differentiation, National Cancer Center Research Institute, Tokyo, Japan.
Sumiko OhnamiDivision of Genetics, National Cancer Center Research Institute, Tokyo, Japan.
Hiromi SakamotoDivision of Genetics, National Cancer Center Research Institute, Tokyo, Japan.
Teruhiko YoshidaDivision of Genetics, National Cancer Center Research Institute, Tokyo, Japan.
Yae KanaiDivision of Molecular Pathology, National Cancer Center Research Institute, Tokyo, Japan.
Masaru KatohDepartment of Omics Network, National Cancer Center Research Institute, Tokyo, Japan.
Takahiro YasuiDepartment of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Kenjiro KohriDepartment of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Tadao KakizoeNational Cancer Center Research Institute, Tokyo, Japan.
Hitoshi NakagamaDivision of Cancer Development System, National Cancer Center Research Institute, Tokyo, Japan.
Nagoya City University · JPNational Cancer Centre Japan · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-muscle invasive (superficial) bladder cancer is a low-grade malignancy with good prognosis, while muscle invasive (invasive) bladder cancer is a high-grade malignancy with poor prognosis. N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) induces superficial bladder cancers with papillary morphology in rats and invasive bladder cancers with infiltrating phenotype in mice. In this study, we analyzed genomic landscapes of rodent BBN-induced bladder cancers using array-based comparative genomic hybridization (array CGH). While no significant copy number alterations were detected in superficial bladder tumors in rats, copy number gains in chromosomal regions 2D-E1, 7qA3, 9F2, and 11C-D were detected in invasive bladder tumors in mice. Amplification of representative genes located on 2D-E1 and 7qA3 chromosomal regions was confirmed by quantitative PCR. Cyp2a22 and Cyp2a5 genes but not Cyp2g1, Cyp2a12, and Rab4b genes on mouse chromosome 7qA3 were amplified in invasive bladder cancers. Although the human ortholog gene of Cyp2a22 has not been confirmed, the mouse Cyp2a5 gene is the ortholog of the human CYP2A6 gene located in chromosomal region 19q13.2, and CYP2A6 was identified by database search as one of the closest human homolog to mouse Cyp2a22. Considering a possibility that this region may be related to mouse 7qA3, we analyzed CYP2A6 copy number and expression in human bladder cancer using cell lines and resected tumor specimens. Although only one of eight cell lines showed more than one copy increase of the CYP2A6 gene, CYP2A6 amplification was detected in six out of 18 primary bladder tumors where it was associated with the invasive phenotype. Immunohistochemical analyses of 118 primary bladder tumors revealed that CYP2A6 protein expression was also higher in invasive tumors, especially in those of the scattered type. Together, these findings indicate that the amplification and overexpression of the CYP2A6 gene are characteristic of human bladder cancers with increased malignancy and that CYP2A6 can be a candidate prognostic biomarker in this type of cancer.

Indexed as

Gene AmplificationGene Expression Regulation, NeoplasticGenomicsPhenotypeAnimalsAryl Hydrocarbon HydroxylasesCell Line, TumorCytochrome P-450 CYP2A6Cytochrome P450 Family 2Gene DosageHumansMaleMiceNeoplasm InvasivenessRatsSyntenyAryl Hydrocarbon HydroxylasesCyp2a5 protein, mouseCYP2A6 protein, humanCytochrome P-450 CYP2A6Cytochrome P450 Family 2

Identifiers

PMID27902773
PMCPMC5130269
OpenAlexW2559197499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.